收费全文 | 1252292篇 |
免费 | 95108篇 |
国内免费 | 1512篇 |
耳鼻咽喉 | 16265篇 |
儿科学 | 40781篇 |
妇产科学 | 34936篇 |
基础医学 | 187615篇 |
口腔科学 | 34676篇 |
临床医学 | 116504篇 |
内科学 | 243955篇 |
皮肤病学 | 27249篇 |
神经病学 | 100982篇 |
特种医学 | 46678篇 |
外国民族医学 | 265篇 |
外科学 | 177902篇 |
综合类 | 25683篇 |
一般理论 | 569篇 |
预防医学 | 103517篇 |
眼科学 | 27942篇 |
药学 | 92180篇 |
6篇 | |
中国医学 | 1950篇 |
肿瘤学 | 69257篇 |
2018年 | 13388篇 |
2017年 | 10305篇 |
2016年 | 11180篇 |
2015年 | 12920篇 |
2014年 | 17925篇 |
2013年 | 27400篇 |
2012年 | 37548篇 |
2011年 | 39921篇 |
2010年 | 22970篇 |
2009年 | 22192篇 |
2008年 | 37737篇 |
2007年 | 40354篇 |
2006年 | 39941篇 |
2005年 | 39063篇 |
2004年 | 37516篇 |
2003年 | 35864篇 |
2002年 | 34779篇 |
2001年 | 55917篇 |
2000年 | 56881篇 |
1999年 | 47740篇 |
1998年 | 12446篇 |
1997年 | 11309篇 |
1996年 | 11708篇 |
1995年 | 11815篇 |
1994年 | 11025篇 |
1993年 | 10318篇 |
1992年 | 38143篇 |
1991年 | 37670篇 |
1990年 | 36435篇 |
1989年 | 35253篇 |
1988年 | 32662篇 |
1987年 | 32024篇 |
1986年 | 30519篇 |
1985年 | 28779篇 |
1984年 | 21927篇 |
1983年 | 19145篇 |
1982年 | 11315篇 |
1981年 | 10263篇 |
1979年 | 20890篇 |
1978年 | 15363篇 |
1977年 | 12711篇 |
1976年 | 11758篇 |
1975年 | 12753篇 |
1974年 | 15520篇 |
1973年 | 15303篇 |
1972年 | 14475篇 |
1971年 | 13522篇 |
1970年 | 12756篇 |
1969年 | 12035篇 |
1968年 | 11205篇 |
Vaccination prevents severe morbidity and mortality from COVID-19 in the general population. The immunogenicity and efficacy of SARS-CoV-2 vaccines in patients with antibody deficiency is poorly understood.
ObjectivesCOVID-19 in patients with antibody deficiency (COV-AD) is a multi-site UK study that aims to determine the immune response to SARS-CoV-2 infection and vaccination in patients with primary or secondary antibody deficiency, a population that suffers from severe and recurrent infection and does not respond well to vaccination.
MethodsIndividuals on immunoglobulin replacement therapy or with an IgG less than 4 g/L receiving antibiotic prophylaxis were recruited from April 2021. Serological and cellular responses were determined using ELISA, live-virus neutralisation and interferon gamma release assays. SARS-CoV-2 infection and clearance were determined by PCR from serial nasopharyngeal swabs.
ResultsA total of 5.6% (n?=?320) of the cohort reported prior SARS-CoV-2 infection, but only 0.3% remained PCR positive on study entry. Seropositivity, following two doses of SARS-CoV-2 vaccination, was 54.8% (n?=?168) compared with 100% of healthy controls (n?=?205). The magnitude of the antibody response and its neutralising capacity were both significantly reduced compared to controls. Participants vaccinated with the Pfizer/BioNTech vaccine were more likely to be seropositive (65.7% vs. 48.0%, p?=?0.03) and have higher antibody levels compared with the AstraZeneca vaccine (IgGAM ratio 3.73 vs. 2.39, p?=?0.0003). T cell responses post vaccination was demonstrable in 46.2% of participants and were associated with better antibody responses but there was no difference between the two vaccines. Eleven vaccine-breakthrough infections have occurred to date, 10 of them in recipients of the AstraZeneca vaccine.
ConclusionSARS-CoV-2 vaccines demonstrate reduced immunogenicity in patients with antibody deficiency with evidence of vaccine breakthrough infection.
相似文献